In a momentous development as reported by the Economic Times, Cipla has brazenly launched a cheaper generic version of Novartis’ Indacetorol (a drug used to treat chronic obstructive pulmonary disease). Cipla has further petitioned to the DIPP to revoke to revoke Novartis’ patents in public interest under S.66 of the Indian patent act. Cipla’s allegations against Novartis in DIPP petition It is reported that Cipla has alleged that the grant of the patent to Novartis is prejudicial to the public...
↧